SG11201808880PA - Pegylated bioactive peptides and uses thereof - Google Patents
Pegylated bioactive peptides and uses thereofInfo
- Publication number
- SG11201808880PA SG11201808880PA SG11201808880PA SG11201808880PA SG11201808880PA SG 11201808880P A SG11201808880P A SG 11201808880PA SG 11201808880P A SG11201808880P A SG 11201808880PA SG 11201808880P A SG11201808880P A SG 11201808880PA SG 11201808880P A SG11201808880P A SG 11201808880PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- quebec
- pct
- rule
- pegylated
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 102100022831 Somatoliberin Human genes 0.000 abstract 1
- 101710142969 Somatoliberin Proteins 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324600P | 2016-04-19 | 2016-04-19 | |
| PCT/CA2017/050475 WO2017181277A1 (en) | 2016-04-19 | 2017-04-18 | Pegylated bioactive peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808880PA true SG11201808880PA (en) | 2018-11-29 |
Family
ID=60039750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808880PA SG11201808880PA (en) | 2016-04-19 | 2017-04-18 | Pegylated bioactive peptides and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9988428B2 (zh) |
| EP (1) | EP3445778B1 (zh) |
| JP (1) | JP7134093B2 (zh) |
| KR (1) | KR102520348B1 (zh) |
| CN (1) | CN109153712B (zh) |
| AU (1) | AU2017254754B2 (zh) |
| BR (1) | BR112018070929A2 (zh) |
| CA (1) | CA3021231A1 (zh) |
| DK (1) | DK3445778T3 (zh) |
| ES (1) | ES2824781T3 (zh) |
| HU (1) | HUE052802T2 (zh) |
| IL (1) | IL262356B2 (zh) |
| MX (1) | MX2018012716A (zh) |
| PT (1) | PT3445778T (zh) |
| RU (1) | RU2748576C2 (zh) |
| SG (1) | SG11201808880PA (zh) |
| WO (1) | WO2017181277A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3947426A4 (en) | 2019-03-29 | 2023-01-04 | The General Hospital Corporation | GHRH OR ANALOGUES FOR USE IN THE TREATMENT OF HEPATIC DISEASE |
| CN116194344A (zh) | 2020-10-09 | 2023-05-30 | 奥托立夫开发公司 | 安全气囊装置 |
| CN114195881B (zh) * | 2021-12-16 | 2022-09-16 | 浙江湃肽生物股份有限公司 | 一种制备醋酸舍莫瑞林的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4689318A (en) | 1985-08-29 | 1987-08-25 | The Salk Institute For Biological Studies | GRF analogs |
| US4914189A (en) | 1987-02-05 | 1990-04-03 | The Adminstrators Of The Tulane Educational Fund | Synthetic GHRH analogs |
| DE3726324A1 (de) | 1987-08-07 | 1989-02-16 | Hoechst Ag | Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute |
| US5023322A (en) | 1988-08-31 | 1991-06-11 | Mta Kutatas-Es Szervezetelemzo Intezete | Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof |
| US5084442A (en) | 1988-09-06 | 1992-01-28 | Hoffmann-La Roche Inc. | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof |
| US5137872A (en) | 1989-09-18 | 1992-08-11 | Pitman-Moore, Inc. | Growth hormone-releasing factor analogs |
| IL98638A (en) | 1990-06-29 | 1995-07-31 | Hoffmann La Roche | Analogs of the factor that releases human growth hormone, their preparation and pharmaceutical preparations that contain them |
| US5847006A (en) | 1991-02-08 | 1998-12-08 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
| AU662731B2 (en) | 1991-04-09 | 1995-09-14 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| CA2158782C (en) | 1994-09-23 | 2010-01-12 | Pierrette Gaudreau | Marker for growth hormone-releasing factor receptors |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| WO1996032126A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
| AU697119B2 (en) | 1995-05-26 | 1998-09-24 | Theratechnologies Inc. | Chimeric fatty body-pro-GRF analogs with increased biological potency |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
| CN1635898A (zh) | 1999-07-26 | 2005-07-06 | 贝勒医学院 | 超级活性的猪生长激素释放激素类似物 |
| EP1324777A1 (en) | 2000-10-05 | 2003-07-09 | Ares Trading S.A. | Regioselective liquid phase pegylation |
| CN1688696A (zh) | 2002-09-18 | 2005-10-26 | 蒙特利尔大学医疗中心 | Ghrh类似物 |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1628676A1 (en) | 2003-05-29 | 2006-03-01 | Theratechnologies Inc. | Grf analog compositions and their use |
| WO2007025988A2 (en) * | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| US20110021429A1 (en) | 2007-10-01 | 2011-01-27 | Pierrette Gaudreau | Renoprotection by growth hormone-releasing hormone and agonists |
| CN101983066B (zh) * | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| EP3473643A1 (en) | 2008-06-12 | 2019-04-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatemnt of cancer |
| CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| EP2699591A4 (en) | 2011-04-21 | 2014-05-07 | Theratechnologies Inc | ANALOGS OF THE GROWTH HORMONE-RELATED FACTOR (GRF) AND USES THEREOF |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| US9079974B2 (en) | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
| CN104946659A (zh) * | 2015-03-27 | 2015-09-30 | 杭州北斗生物技术有限公司 | 重组人生长激素的制备方法及其peg化修饰物的制备方法 |
| US20170037105A1 (en) | 2015-08-03 | 2017-02-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
-
2017
- 2017-04-18 SG SG11201808880PA patent/SG11201808880PA/en unknown
- 2017-04-18 CN CN201780021914.8A patent/CN109153712B/zh active Active
- 2017-04-18 KR KR1020187033365A patent/KR102520348B1/ko active IP Right Grant
- 2017-04-18 HU HUE17785199A patent/HUE052802T2/hu unknown
- 2017-04-18 PT PT177851995T patent/PT3445778T/pt unknown
- 2017-04-18 US US15/490,618 patent/US9988428B2/en active Active
- 2017-04-18 BR BR112018070929-8A patent/BR112018070929A2/pt unknown
- 2017-04-18 US US16/094,565 patent/US10918730B2/en active Active
- 2017-04-18 CA CA3021231A patent/CA3021231A1/en active Pending
- 2017-04-18 JP JP2018555634A patent/JP7134093B2/ja active Active
- 2017-04-18 DK DK17785199.5T patent/DK3445778T3/da active
- 2017-04-18 ES ES17785199T patent/ES2824781T3/es active Active
- 2017-04-18 WO PCT/CA2017/050475 patent/WO2017181277A1/en active Application Filing
- 2017-04-18 MX MX2018012716A patent/MX2018012716A/es unknown
- 2017-04-18 AU AU2017254754A patent/AU2017254754B2/en active Active
- 2017-04-18 RU RU2018140501A patent/RU2748576C2/ru active
- 2017-04-18 EP EP17785199.5A patent/EP3445778B1/en active Active
-
2018
- 2018-10-14 IL IL262356A patent/IL262356B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL262356B2 (en) | 2023-06-01 |
| US9988428B2 (en) | 2018-06-05 |
| HUE052802T2 (hu) | 2021-05-28 |
| RU2018140501A (ru) | 2020-05-19 |
| WO2017181277A1 (en) | 2017-10-26 |
| DK3445778T3 (da) | 2020-10-12 |
| ES2824781T3 (es) | 2021-05-13 |
| JP7134093B2 (ja) | 2022-09-09 |
| AU2017254754B2 (en) | 2021-02-04 |
| US20170296628A1 (en) | 2017-10-19 |
| RU2748576C2 (ru) | 2021-05-27 |
| US20190209699A1 (en) | 2019-07-11 |
| JP2019516675A (ja) | 2019-06-20 |
| KR20180135016A (ko) | 2018-12-19 |
| IL262356A (en) | 2018-11-29 |
| CN109153712A (zh) | 2019-01-04 |
| CN109153712B (zh) | 2022-09-16 |
| RU2018140501A3 (zh) | 2020-09-08 |
| PT3445778T (pt) | 2020-10-15 |
| EP3445778A1 (en) | 2019-02-27 |
| EP3445778B1 (en) | 2020-07-15 |
| AU2017254754A1 (en) | 2018-11-01 |
| MX2018012716A (es) | 2019-02-11 |
| EP3445778A4 (en) | 2019-05-01 |
| KR102520348B1 (ko) | 2023-04-10 |
| BR112018070929A2 (pt) | 2019-02-26 |
| CA3021231A1 (en) | 2017-10-26 |
| US10918730B2 (en) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201810102SA (en) | Glucagon-receptor selective polypeptides and methods of use thereof | |
| SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201903462UA (en) | Methods of delivering a neuroprotective polypeptide to the central nervous system | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201809229VA (en) | Pharmaceutical composition | |
| SG11201808880PA (en) | Pegylated bioactive peptides and uses thereof |